Centre for Commercialization of Regenerative Medicine
ON, Canada
Help to commercialize cell and gene therapies and regenerative medicine technologies
grant_single_labels|summary
grant_single|eligibleFinancing
- grant_single|noCondition
grant_single|deadlines
- grant_single|timelineUnspecified
grant_single|financingType
Partnering and Collaboration
grant_single|eligibleIndustries
- Manufacturing
grant_single|grantors
- Centre for Commercialization of Regenerative Medecine
grant_single|status
grant_card_status|open
grant_single_labels|preview
Access business services, regulatory expertise, technical services and a 40,000 square foot custom built facility for cell and gene therapy manufacturing in Toronto.
grant_single_labels|projects
grant_single|admissibleProjectsExample
$875,000
Pilot clinical trial for new cell therapy at the Toronto manufacturing facility
$550,000
Design a software platform for cell therapy logistics at the Toronto facility
$1,000,000
Create a bioreactor to scale-up gene therapy production at the Toronto facility
$475,000
Launch a training program for gene therapy manufacturing at the Toronto facility
$600,000
Establish a regulatory consultation service for gene therapy startups in the Toronto facility
$750,000
Develop a cell therapy for chronic illnesses by using a custom-built facility
grant_single_labels|admissibility
Eligibility criteria for this grant:
- Applicants must be companies operating at the interface between academia and industry.
- Projects must involve manufacturing challenges in areas like process development, analytics, and commercial GMP-compliant manufacturing.
- Preference given to projects in cell and gene therapies, with a focus on advancing therapies towards the clinic.
grant_eligibility_criteria|who_can_apply
The context provided does not detail specific eligibility criteria for a grant application directly related to CCRM's services. However, typically, the type of entities that may be interested in reaching out or exploring collaboration with CCRM include companies or research entities at the interface of academia and industry that are focused on cell and gene therapy manufacturing, require process development, and are aiming to transition from pre-clinical to GMP-compliant manufacturing stages. These may include small biotechs, large pharmaceutical companies, or research organizations involved in developing innovative therapies. Prospective partners are likely engaged in:- Manufacturing challenges needing technical support or solutions.- Cell and gene therapy development.- Seeking to scale from pre-clinical to commercial manufacturing.- Engaging in collaborative processes for technological and manufacturing development.- Needing infrastructure and resources for GMP-compliance and process continuity from lab to market.
grant_eligibility_criteria|eligible_expenses
The activities eligible for this grant are focused on addressing manufacturing challenges and advancing manufacturing processes for cell and gene therapies. This involves collaboration and utilization of specialized infrastructure and technologies to streamline production and ensure compliance with industry standards.
- Tackling manufacturing challenges at the interface between academia and industry.
- Accessing process development and analytics services for cell and gene therapies.
- Availing pre-clinical to commercial GMP-compliant manufacturing services.
- Collaborating with an industry-leading team, including 55+ PhDs, for specialized expertise.
- Using enabling technologies through industry partnerships for advanced manufacturing solutions.
grant_eligibility_criteria|zone
The grant covers specific expenses directly related to collaboration and development in the field of cell and gene therapies.
- Technical consulting fees for development and manufacturing process design.
- Costs associated with process development and analytics services.
- Expenses for GMP-compliant manufacturing services from pre-clinical to commercial stages.
- Access and utilization fees for specialized infrastructure and enabling technologies.
- Collaborative project expenses directly related to addressing manufacturing challenges.
grant_single_labels|criteria
There are evaluation and selection criteria for this grant. The criteria include:
- Technical expertise and alignment with project goals
- Demonstrated collaborative approach to problem-solving
- Potential for successful process development and manufacturing
- Track record of delivering complex projects on time and on budget
grant_single_labels|register
- Submit a grant application through the official portal or contact CCRM directly.
- Engage in a thorough assessment with CCRM technical experts to understand your specific needs.
- Collaborate with CCRM to identify process pain points, tools, and technologies for your program.
- Execute the manufacturing plan with CCRM's team to achieve cost-effective and efficient outcomes.
grant_single_labels|otherInfo
Here are additional relevant details for this grant:
- The collaboration with CCRM provides access to 55+ PhDs, ensuring significant specialized expertise to support projects.
- CCRM boasts state-of-the-art facilities that are accessible for remote viewing, which can provide potential applicants with an insight into the possibilities for their projects.
- CCRM has a strong track record, having supported three IND filings since 2019, indicating a proven capacity to aid in regulatory processes.
- The collaboration with CCRM includes co-located process development and GMP-compliant manufacturing, ensuring seamless transition and process continuity from lab development to full-scale production.
- Customer testimonials showcase successful collaborations, reflecting CCRM's effectiveness in improving manufacturing timelines and processes.
Apply to this program
Accelerate Your Cell and Gene Therapy Innovations
CCRM is introducing an opportunity designed to support and scale companies working at the intersection of academia and the cell and gene therapy industry. This initiative aims to leverage cutting-edge technologies and extensive expertise to overcome manufacturing challenges and expedite the journey from lab to clinical applications.
Dive Deeper Into the Unique Resources Provided by CCRM
CCRM stands as a beacon for companies operating within the cell and gene therapy landscape, offering a unique blend of expertise, infrastructure, and support necessary for successful biotechnology ventures. The initiative provides access to 55+ PhDs with specialized expertise in this complex field, serving as a powerhouse of knowledge for budding and scaling businesses alike. By partnering with innovative technology providers and maintaining industry-leading processes, CCRM equips companies with all the necessary tools to streamline their development and manufacturing workflows.
Designed with an emphasis on collaboration, CCRM presents itself as an extension of your own team, ensuring that every project receives a thoroughly customized approach. This is underpinned by a robust process development lab and GMP-compliant clean rooms, allowing for continual process continuity from pre-clinical research straight through to commercial manufacturing. For businesses seeking rapid progress toward clinical trials, CCRM provides not only the physical infrastructure but also the crucial strategic partnership framework to help break through the complexities inherent in manufacturing biological therapies.
The grant emphasizes customer-centric manufacturing processes that begin with thorough assessment. CCRM's technical experts work closely with clients to design tailored development and manufacturing plans that directly address unique program needs. As these plans move into the execution phase, the partnership ensures they're carried out on time and within budget, a true testament to CCRM’s expertise in managing complex projects.
Furthermore, the initiative showcases its strength through past successful collaborations: with Nkarta for natural killer cell products, with DiscGenics for allogeneic therapy solutions, and with Avectas for the SOLUPORE™ intracellular delivery platform. Each collaboration not only represents a milestone achievement but also underscores CCRM's commitment to enabling cost-effective, timely, and innovative project outcomes.
The significance of CCRM’s offering can't be overstated, especially for those in a race to bring novel therapies to clinic. Beyond the tangible benefits of advanced facilities and expert guidance, businesses also gain access to a broad network of strategists and partners, amplifying their potential for innovation and impact.
In conclusion, for companies seeking to accelerate their cell and gene therapies from the lab to the marketplace, CCRM provides an unparalleled fusion of expertise, technology, and strategic partnership, ensuring innovative ideas become successful, market-ready therapies.
